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One Sentence Summary: This paper involves discussing, describing, and characterizing
biomarkers that have been proposed to aide in the diagnosis of benign gynecological disorders
including endometriosis and polycystic ovary syndrome.
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Abstract: Benign gynecological disorders can affect a high percentage of women of
reproductive age, ages 15-44 years. These conditions can affect the lifestyle of the individual and
can be associated with infertility. The gold standard to identify and diagnose endometriosis
requires invasive surgical procedures, while the Rotterdam Criteria is used to identify and
diagnose polycystic ovary syndrome. The purpose of this paper is to discuss, describe, and
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characterize potential non-invasive biomarkers that are present in various pathological stages of
both endometriosis and polycystic ovary syndrome. These biomarkers include CA125, Serum
galectin-9, hsa-miRNA-154-5p, miRNA-93, miRNA-320 and ET-1, miRNA-222, miRNA-146a,
and miR-30c used in a panel1-6.
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Abbreviations: CA125= Cancer Antigen 125; PCOS= Polycystic Ovary Syndrome, MiRNA= MicroRNA; MMP= Metalloproteinases; EMT=
Epithelial to Mesenchymal Transition; TGF ß-1=Transforming Growth Factor ß-1; VEGF=Vascular Endothelial Growth Factor; NGF=Nerve
Growth Factor; rASRM=American Society for Reproductive Medicine; CVF=Cervicovaginal Fluid; Gal=Galectins; mRNA= Messenger RNA;
GLUT4=Glucose Transporter Type 4; MCM7=Minichromosomal Maintenance Complex Component 7; ET=Endothelin; 2D-DIGE=Two
dimensional Difference Gel Electrophoresis; LC-MS=Liquid Chromatography-Mass Spectrometry; TMT=Tandem Mass Tags; SDS-PAGE=
Sodium Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis; CS= Eutopic tissue from asymptomatic controls scheduled for risk-reducing
surgery with no evidence of disease at laparoscopy in the secretory phase; CP= Eutopic tissue from asymptomatic controls scheduled for riskreducing surgery with no evidence of disease at laparoscopy in the proliferative phase; PS= Eutopic tissue from patients with chronic pelvic pain
with no evidence of endometriosis at laparoscopy in the secretory phase; ES=Eutopic tissue from endometriosis cases in the Secretory phase and
EcS= ectopic tissue from endometriosis cases in the secretory phase; EP=Eutopic tissue from endometriosis cases in the proliferative phase;
LUM=Lumican; TPM2=Tropomyosin beta-chain; ECM=Extracellular Matrix; RT-PCR=Reverse Transcription-Polymerase Chain Reaction;
ROC=Receiver Operating Characteristic Curve; IR=Insulin Resistance; KEGG Pathway=Kyoto Encyclopedia of Genes and Genomes;
ERK=Extracellular-Signal-Regulated Kinase; ANOVA=One-Way Analysis of Variance; ELISA=Enzyme-Linked Immunoassay; CPP=Chronic
Pelvic Pain;
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Introduction
Benign gynecological disorders are a complex group of medical conditions in which both
the symptoms and severity, are not specific to one particular disorder. A biomarker is “a defined
5

characteristic that is measured as an indicator of normal biological processes, pathogenic
processes or responses to an exposure or intervention”7. The idea of potential biomarkers
emerged through human and animal model systems, to identify associations between biological
measurements and prototypes of the disease at various levels. Clarity on these measurements and
the effectiveness of the biomarkers for several contexts or uses, in the document “Biomarker,
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EndpointS, and other Tools” serves as an excellent resource. Biomarkers can be used to provide
therapeutic interventions ranging from molecular, histologic, radiographic, or physiologic
characteristics. There are various types of biomarkers characterized by their function including
diagnostic, monitoring, pharmacodynamic/response, predictive, safety, susceptibility/risk, and
prognostic and predictive biomarkers. This paper will focus on diagnostic biomarkers. These are
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biomarkers which “detect or confirm the presence of a disease or condition of interest or
identifies an individual with a subtype of the disease”7. Generally, the validation of a biomarker
starts at analytical validation. A biomarker must then be qualified using an evidentiary
assessment and utilization. The biomarker can then be validated, measured reliably, precisely,
and repeatably at a low cost. The diagnostic biomarker is specifically evaluated using receiver-
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operating characteristic (ROC) curves8. Classifying these biomarkers by sensitivity and
specificity percentages determines the efficacy of each biomarker for potential diagnosis9. The
sensitivity measure portrays the efficiency of a test and how accurate it can identify the presence
of the disease. The specificity is a measure that states how well the test can identify the lack of a
condition or disease in an individual9.
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Two common benign gynecological disorders are endometriosis and polycystic ovary
syndrome (PCOS)2. Currently, there are no biomarkers that allow for a conclusive or a direct
diagnosis for these specific benign gynecological conditions. This paper will therefore mainly
characterize pre-clinical biomarkers for these conditions. A secondary objective of this paper is
5

to determine the role miRNAs play as a pre-clinical non-invasive biomarker of PCOS and
endometriosis and evaluate its possible relationship with hyperandrogenemia and insulin
resistance (IR)4,10.

Presentation, Pathogenesis and Diagnosis of Endometriosis
10

Although the exact cause of endometriosis is unknown, this estrogen-dependent
inflammatory disease is diagnosed by the presence of endometrial glands and stroma outside of
the uterine cavity. The condition may present as asymptomatic, or with varied and nonspecific
presentations, creating the complexity of the condition and diagnosis. Globally, approximately
10 percent of women of reproductive age can be affected by the condition with the highest
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prevalence at ages between 25 to 35 years11. Additionally, a smaller percentage of premenarcheal
girls and postmenopausal women are affected. There are various locations where the lesions can
be present, including the pelvis, the bowel, diaphragm, and pleural cavity. Due to inflammation,
hallmarks of the disease include dysmenorrhea, dyspareunia, chronic pain, and infertility12.
Development of ectopic endometrial lesions
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There are several theories regarding how ectopic endometrial tissue develops in locations
outside of the uterus. These theories include altered immunity, imbalanced cell proliferation and
apoptosis, aberrant endocrine signaling, and genetic factors12. The theory of retrograde
menstruation is the hypothesis in which cells move through the fallopian tubes and enter the
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peritoneal cavity13. This theory cannot explain all cases of endometriosis because retrograde
menstruation can be present in up to 90 percent of all women, but only 10 percent of women
present with endometriosis. Another theory explaining the presence of ectopic endometrial cells
include mesothelium, stem cells, Mullerian rests, bone marrow stem cells, embryonic vestiges
5

with lymphatic or vascular dissemination, and coelomic metaplasia14.
Clinical presentation of endometriosis
The hallmarks of the endometriosis include dysmenorrhea, dyspareunia, chronic pain,
and infertility. Pelvic pain specifically can be associated with inflammation, pain mediators,
along with neurologic dysfunction. Other endometriosis-related pain is due to a combination of
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increased nerve fibers and an imbalance of sympathetic and sensory nerve fibers15,16.
Specifically, pain is the result of estrogen repulsing sympathetic axons by acting as a
neuromodulator while sensory innervation is preserved. Additionally, pain in the CNS can be
due to the stimulation of the peripheral nerve sensitization through inflammation. A patient can
present with dysmenorrhea around one to two days before, during, and after menses. Pelvic pain

15

can be characterized from dull, throbbing, sharp and/or burning and are associated with an
adnexal mass17. Additional symptoms include bowel and bladder dysfunction, abnormal uterine
bleeding, low back pain, or chronic fatigue12.
Endometriosis can be characterized by the presence of specific symptoms, location of the
lesion, along with how the lesion disrupts the organ or tissue where it is found. The most
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common sites of endometriosis are the ovaries, anterior and posterior cul-de-sac, posterior broad
ligaments, and uterosacral ligaments, the less frequent locations include uterus, fallopian tubes,
sigmoid colon and appendix18,19. Endometriosis can be categorized based on depth of invasion,
e.g. superficial peritoneal, ovarian, and deeply infiltrating endometriosis. Deeply infiltrating
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endometriosis is distinguished by a solid mass located in the peritoneum deeper than about 5
mm20. These endometriosis implants can be distinguished from eutopic endometrium by their
fibrous tissue, blood, and cysts. During the process of inflammatory cells breaking down red
blood cells, both hemosiderin-laden macrophages and pigmented histiocytes form. The increased
5

pigment dates the older lesion21. Superficial peritoneal lesions can present with or without
glandular or stromal components. That can be changed by cellular atypia and pigmented
histiocytes, respectively22. Peritoneal or deeply infiltrating endometriosis can result in bladder
endometriosis, bowel endometriosis, endometriosis of the abdominal wall, and thoracic
endometriosis. Peritoneal or deeply infiltrating endometriosis lesions that appear on the
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uterosacral and cardinal ligaments and pouch of Douglas are associated with dyspareunia20.
Various urinary symptoms can be exhibited in women with bladder endometriosis. Finally,
women with bowel endometriosis can present with symptoms such as diarrhea and
constipation13. Ovarian lesions or endometrioma formed after ectopic endometrial tissue within
the ovary bleeds resulting in a hematoma surrounded by duplicated ovarian parenchyma. These
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endometriomas are characterized by fibrotic walls and surface adhesions23.
Diagnosis of endometriosis
Although endometriosis can only be diagnosed through histological examination of a
biopsied lesion using surgery, usually laparoscopy, information gathered through the presence of
symptoms, physical examination, laboratory, and imaging findings allows for identifying both
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location and size of the implants that would support a presumptive diagnosis24. These additional
findings could include the presence of adnexal masses or a tenderness on a vaginal examination.
Findings via imaging using transvaginal ultrasound and MRI can show ovarian cysts and
modules of the rectovaginal septum suggesting endometriosis. Identifying non-invasive
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biomarkers are beneficial since there are no laboratory findings indicative of the presence of the
condition12.
The gold standard to certainly diagnose the condition is through laparoscopic surgery13.
With laparoscopy, the condition is scored using the rASRM score from a I-IV or minimal to
5

severe (Figure 1)10. The method involves creating small incisions to remove mild to moderate
endometriosis in internal organs and remove scar tissue. This procedure, using a laparoscope,
lasers, and other operative procedures functions as an alternative to open abdominal surgery. The
risks to this include pelvic infection, uncontrolled bleeding, post-surgical scar tissue formation,
and bowel, bladder, or uterus damage25. Laparoscopy can show areas of peritoneal endometriosis
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that present “as raised flame-like patches, whitish opacifications, yellow-brown discolorations,
translucent blebs, or reddish or reddish-blue irregularly-shaped islands,”12.
On a hormonal and cellular level, endometriosis includes abnormalities in steroid
hormone production and the presence of various eutopic and ectopic receptors. Endometriosis is
characterized by estrogen dependence and progesterone resistance presented with chronic
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inflammation. Histologically, patients with endometriosis present with abnormal levels of
VCAM-1 (CD-106) and ICAM-1 (CD-54) within their serum, as well as MMP-2 and MMP-9,
two types of metalloproteinases used to remodel extracellular matrix at the site of implantation26.
This is notable when understanding the EMT since endometriosis presents with an invasive
mesenchymal phenotype. Here N-cadherin is gained, and E-cadherin is lost with promoting
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factors such as TGF ß-1 present13. There are only a few studies that present a genetic cause for
endometriosis showing a minor effect at multiple loci16. One study relayed that, somatic
mutations in the genes ARID1A, PIK3CA, KRAS, and PPP2R1A, which are cancer driver genes,
can lead to the onset of endometriosis lesions27.
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Currently, the lack of clinically accepted biomarkers to detect the stage of disease without
invasive surgery makes this research increasingly relevant and necessary. To be an effective
biomarker, which can include cells, proteins, or lipids, these biomarkers should be identified in
extractable body fluids such as blood, urine, saliva, and cervicovaginal fluid (CVF) and would
5

need to be identified at a stage of pathogenesis13. Being identified in CVF would be the most
effective, since the biomarkers localized in that area would have increased sensitivity and
specificity. The endometriosis biomarkers that will be discussed in this paper includes miRNAs,
Gal, specifically Gal-9, and Endothelin-11,4.
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Potential Non-Invasive Biomarkers for Endometriosis: CA-125 and Gal-9 and hsa-miRNA154-5p
Identifying CA125 as a Hormonal Biomarker for Endometriosis
CA125 was determined to be the most effective marker for ovarian cancer with a clinical
threshold of 35 U/mL28. CA125 was tested to see if it could serve as an effective diagnostic
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marker for endometriosis. On a broader scale, this study sought to identify numerous potential
biomarkers by examining the expression of all the proteins present in eutopic and ectopic
endometrial tissue specimens. These specimens, obtained from the University College London
Hospital Gynecology Department, were taken from individuals who were positive for
endometriosis. The samples for the controls were taken from women who lacked the onset of
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endometriosis but had a family history of cancer and therefore wanted to undergo exploratory
surgery due to a presence of Chronic Pelvic Pain (CPP). Individuals who were part of the study
consisted of women diagnosed with endometriosis using laparoscopy and further enforced
histologically. The controls were divided into two groups: controls with and without pain. 21
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women, part of the control with pain group, were characterized by individuals with pelvic pain
stemming from a chronic pelvic inflammatory disease with no surgery or an unknown cause. The
21 individuals who were part of the controls without pain included women who were undergoing
normal menstrual cycles with no identification of endometriosis post-surgery but were
5

undergoing bilateral tubal ligation and/or prophylactic bilateral salpingoophorectomy2.
The researchers first collected these samples prior to the proteomic profiling methods.
These methods included protein extraction, quality assessment, immunodepletion, and pooling.
After staining using SDS-PAGE with colloidal Coomassie Blue staining, tissues samples were
further excluded from the study if the stains were excessively polluted with blood proteins. This
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was because the abundance of blood proteins hindered the presence of the tissue-derived
proteins. Samples with very low protein expression were also excluded. The samples that were
included were then divided based on clinical group and cycle phased which then resulted to six
groups of 6-20 tissue samples per group labeled CS, CP, PS, ES and EcS. By proteomic profiling
using 2D-DIGE, proteins identified include LUM and TPM2, which both had a higher
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expression in the secretory phase of endometriosis when compared to the control groups. By
proteomic profiling using 3D-LC-MS/MS with TMT labelling, the proteins identified were
further analyzed for functionality by using the GO biological process and the KEGG pathway
which determined that the proteins played a role in metabolic pathways, ribosome, proteasome,
spliceosome, and regulation of the actin cytoskeleton, focal adhesions and extracellular matrix-
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receptor interactions. The proteins that were highly expressed in ectopic versus eutopic tissue
that had functionality associated with muscle included TPM1-4, MYLK, MYL6 and 9, PDLIM7,
CNN1, CALD1, and TAGLN. Other proteins with increased expression in ectopic tissue
included FN1, LUM, COL1A2, COL6A1, COL6A3, COL14A1, PRELP, OGN, DCN, BGN,
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FMOD, and MFAP4. These protein groups were then compared and scores for biomarker
potential were determined (Table 1) 2.
It is noteworthy to mention that even by using proteomic approaches described, CA125
was unable to be found due to this heterogeneously glycosylated protein’s large size and low
5

abundance2. It is also important to understand that in the pathogenesis of endometriosis proteins
that play a role in cytoskeletal, ECM organization, and cell-matrix are vital. During implantation
of ectopic endometrial cells, for the cells to adhere to the peritoneal ECM and for the retrogradeshed endometrial cells to be able to invade, these ECM proteins would be beneficial29.
The expression of CA125 and sICAM1 were compared between endometriosis and the
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control groups and showed to have the significantly increased expression. The results showed
40% sensitivity and 90% specificity. The area under the ROC curve for endometriosis versus
pain group was 0.713. CA125 alone provided data at 40% sensitivity and 90% specificity. It was
concluded that CA125 couldn’t exist as a diagnostic marker alone. CA125 doesn’t have the
equivalent diagnostic accuracy in endometriosis as it does in ovarian cancer as its median level
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in the samples of endometriosis falls under that threshold2.
In summary, CA125 was also shown to be the most effective when included in the best
model for secretory phase samples along with MIF and PAEP with a sensitivity of 65% at 80%
specificity (Table 2)2. It was concluded that CA125, s1CAM1, PAEP, MIF, and FST are
potentially useful diagnostic markers when combined in multivariate models. These results
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indicate that the biomarkers are cycle dependent2.
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Gal-9 Serving as a Non-invasive Biomarker for Endometriosis
Lectins are proteins that bind to carbohydrates. Galectins are a type of lectin of that bind
at the ß-galactoside and play a role in cell growth, adhesion, apoptosis, and angiogenesis30.
Lectins have been associated with reproductive immunology, inflammation, and autoimmunity.
5

These molecules are carbohydrate-binding proteins that associate with sugar groups causing
agglutination. Previous studies have shown that a normal endometrium may contain Gal-1-4, 79, and 12. Out of those, Gal-1 and Gal-3 have specifically been associated with the pathogenesis
of endometriosis1.
Gal-9 has specifically been tested because of its exclusive expression in the normal
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endometrium by epithelial cells. This molecule, a bidirectional immunomodulator, could be a
marker of endometrial receptivity pre-implantation1. In previous studies it was seen that there
was an increased Gal-9 staining in the ectopic endometriosis lesions, which is what led to further
studies to identify Gal-9 as a diagnostic potential of being a serum soluble measurement31.
Specifically, it was found that during implantation and the early pregnant decidua, Gal-9 was
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only expressed by uterodomes32. Additionally, Gal-9 mRNA was shown to downregulate IFNgamma production in NK cells meaning that there could be a role for Gal-9 when regulating the
fetomaternal immunotolerance by navigating the cytotoxicity of NK cells33.
The Brubel study identified 135 women of reproductive age and then divided them into
77 endometriosis patients, 28 gynecologic controls, and 30 healthy women. The endometriosis
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study group was divided into mild and moderate groups. 20 individuals were a part of the mild
group, who had stages I-II endometriosis and 57 patients were part of the moderate to severe
group, consisting of women who had stages III-IV endometriosis. This group usually had a
previous surgery and had CPP1.
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A RT-PCR assay was performed to determine the gene expression of LGALS9 gene
expression in the eutopic endometrium of patients with and without endometriosis along with
ectopic endometriotic implants. The expression density of Gal-9 mRNA to RibS9 were then
normalized to assess the expression of LGALS9 transcripts and the densitometry of Gal-9
5

mRNA. The results were statistically analyzed using the t-test and the Mann-Whitney U-test.
Data was presented using the ELISA test and the ASRM score. To compare the mean or medians
of Gal-9, analyses such as the nonparametric Kruskal-Wallis H-test with Dunn’s comparison or
the ANOVA test with Bonferroni’s correction were used. It is notable to mention here that the
results of this study suggest that other components of the peritoneal fluid have the capability of
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producing this lectin since an increased expression of Gal-9 was found in the peritoneal cells.
Additionally, it was proven that Gal-9 was directly expressed by the ectopic implant as opposed
to its surrounding areas when both locations were compared1.
The results from the ELISA test showed increased levels of Gal-9 in minimal-mild and
moderate-severe endometriosis when compared with healthy controls. The biomarker showed
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94% sensitivity at 93.75% specificity (Figure 2)1. It was also concluded that benign gynecologic
conditions related to CPP, or infertility might be associated with elevated serum Gal-9 levels.
Through the study, Gal-9 was determined to be a new potential biomarker for non-invasive
laboratory diagnosis of endometriosis. It was proved to diagnostically perform better than CA125 and VEGF. Further studies include expanding the sample size to include a larger subgroup
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of gynecologic controls to address early-stage non-invasive diagnostic testing1.
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hsa-miRNA-154-5p Serving as a Non-invasive Biomarker for Endometriosis
MiRNA is a biomarker that plays a part in the detection of both endometriosis and PCOS
at varied capacities. Specifically, to endometriosis, miRNA expression changes between patients
that have eutopic endometrium with endometriosis and those with a healthy endometrium and
5

ectopic lesions. These miRNAs are involved in various pathways that are part of processes such
as proliferation, inflammation, and angiogenesis34. MiRNAs show potential as biomarkers due to
these disease-related differences. These non-coding RNAs are secreted by exosomes and
circulate through its associated RNA-binding proteins, the Ago2 component of the RNA-induced
silencing complex (RISC), and nucleoplasmin (NPM1)35,36.
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The specific plasma miRNA signature that was found to be associated with endometriosis
in this study was hsa-miRNA-154-5p which is located at the DLK1-MEG3 imprinted genomic
locus37. This locus contains “multiple maternally expressed noncoding RNA genes and
paternally expressed protein-coding genes”38. This specific mRNA is found in carcinosarcomas
allowing for the epithelial-to-mesenchymal transition to be detected39. Hsa-miRNA-154-5p has
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also been associated with endometriomas and endometrial stroma decidualization40.
51 patients with endometriosis were compared with 41 controls determining the changes
in extracellular miRNA spectra in plasma. There were three phases of this study including
biomarker screening, discovery, and validation. The expression of the miRNAs was analyzed
using quantitative PCR-based microarrays. The diagnostic performance was further statistically
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analyzed using in silico bioinformatics modelling and ROC curve3.
In this study, the 42 DE-miRNAs (differentially expressed miRNAs) were studied using a
q-PCR-based profiling array to identify putative biomarkers for the disease. The parameters used
from the mi-RNAs include BMI, age, and dysmenorrhea. This showed discrimination between
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the controls and patients with endometriosis when comparing specificity and sensitivity values
for a small sample set3.
The main takeaway is that after the ROC curve analysis, that was performed on the
cohort of 64 cases and controls, it was seen that DE hsa-miRNA-154-5p had an AUC value of
5

0.72 (95% confidence interval [Cl]: 0.587, 0.851, P=0.001) with the sensitivity and specificity
values being 67% and 68% (Figure 3C) 3. It was found that hsa-miR-154-5p has sensitivity and
specificity values high enough to discriminate patient with endometriosis from controls3. When
the clinical parameters of age and BMI were combined with that of the four DE miRNA
including hsa-miR-196b-5p, hsa-miR-378a-3p, and hsa-miR-33a-5p, the prediction validity
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improved substantially but the AUC value for endometriosis prediction did not change (Figure
3D) 3.

Pathogenesis and Relevance of PCOS
PCOS is one of the most common endocrine disorders and affects 7-9% of the women
15

who are of reproductive age5. The complexity of this condition is due to its multiple etiologies
along with it being a diagnosis of exclusion. PCOS is characterized by menstrual irregularities,
abnormal ovarian size, and hyperandrogenism. Along with the ruling out other clinical
conditions, the Rotterdam Criteria is used to diagnose PCOS. The Rotterdam Criteria states that
2 of the following 3 criteria is needed for diagnosis. The criteria include oligo- and/or
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anovulation, clinical and/or biochemical signs of hyperandrogenism, and polycystic ovaries
visualized by ultrasound. A transvaginal ultrasound is used to determine the presence of
polycystic ovarian morphology (PCOM), which is 12 or more follicles in either ovary measuring
2-9 mm in diameter, and/or increased ovarian volume (>10 mL). History and physical exam can
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be used to identify irregular menses and hyperandrogenic features. However, beyond that, PCOS
can only be diagnosed if other conditions that mimic PCOS with oligo/anovulation and/or
hyperandrogenic symptoms are excluded. The conditions include but are not limited to thyroid
disease, nonclassical congenital adrenal hyperplasia (NCCAH), hyperprolactinemia, and
5

androgen-secreting tumors5.
The clinical hallmarks of PCOS include oligomenorrhea and hyperandrogenism along
with hirsutism and polycystic ovaries41. The complexity of this condition is because these
features are not necessarily always present or can be evident in varying degrees. This complexity
results in a slew of evaluation tests based on symptoms. A transvaginal ultrasound is not
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necessary when a patient presents with both oligomenorrhea and hyperandrogenism along with
when other differential conditions are ruled out. It must be noted that a transvaginal ultrasound
with polycystic ovaries alone does not confirm the diagnosis of PCOS41. Conditions that need to
be ruled out include hyperprolactinemia, thyroid disease, and pituitary tumors inhibiting
gonadotropic secretion. The evaluation that can be used specifically to exclude similar disorders
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include thyroid-stimulating hormone level, prolactin level, 17-hydroxyprogesterone, oral GTT,
lipid panel, and 24-hr urine free cortisol42. PCOS may also result in increased risk for associated
conditions such as obesity, risk for diabetes mellitus, hypertension, lipid abnormalities, sleep
disorders, depression, and metabolic syndrome42. About 60-70% of PCOS patients demonstrate
insulin resistance5.
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Hyperandrogenism in PCOS
As stated previously, one of the hallmarks of PCOS is hyperandrogenism, which is due to
increased gonadotrophin secretion of luteinizing hormone (LH) from the pituitary. Specifically,
ovarian theca cells secrete high levels of androgens, such as testosterone, from the LH secretion
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leading to hyperandrogenism. Symptoms of hyperandrogenism include acne, hirsutism, and
male-pattern balding or hair loss. It is advised that patients who present with hyperandrogenism
alongside with oligo-ovulation undergo biochemical testing to serum androgens. Hirsutism is
characterized by the presence of terminal hair longer than 5 mm with pigment and shape. This
5

presentation is graded by using the modified Ferriman-Gallwey (mFG) score in nine areas of the
body with scores from 0 to 4 and a total score of 36. A mFG score greater than 6 is defined as
hirsutism. Differentials that need to be ruled out regarding hyperandrogenism include nonclassical congenital adrenal hyperplasia (NCCAH), androgen-secreting tumor, and ovarian
hyperthecosis41. Patients with both hyperandrogenic symptoms and oligomenorrhea are advised
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to undergo testing for serum total testosterone and an early morning 17-hydroxyprogesterone.
Serum total testosterone is determined and identified using liquid chromatography-tandem mass
spectroscopy (LC-MS/MS). Severe hyperandrogenism has serum testosterone levels at >150
ng/dL, with normal levels at 45-60 ng/dL41.
Oligo-ovulation in PCOS
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Clinically, women with PCOS, may present with oligo-ovulation or anovulation in
coordination with polycystic ovarian morphology (PCOM) and/or increased ovarian size. Oligoovulation is defined as menstrual cycles that stray from the normal cycle length of 21-35 days,
with menstrual bleeding less frequent than once a month. Oligomenorrhea or amenorrhea, which
is the lack of menstrual bleeding, is present in about 70%-80% of women with PCOS. An
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abnormal ovarian size has an increased volume of 10 mL3 and/or follicles that are between 2 and
9 mm in size in 1 ovary42. Another hallmark of PCOS is the ovary with follicles that have
increased resistance to follicle stimulating hormone (FSH). Finally, the presence of increased
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anti-Mullerian hormones secreted by preantral follicles in the granulosa cells is associated with
this condition42.

Potential Non-Invasive Biomarkers for PCOS: miRNAs
5

MiRNAs are the most prominent type of biomarkers used for gynecological disorders.
MiRNAs serve multiple critical regulatory functions at the post-transcriptional level including
cell proliferation, differentiation, survival and apoptosis, and the stress response. These noncoding molecules are characterized by single strands of RNA that are 18-24 nucleotides in
length. These molecules induce degradation or inhibit protein translation after the miRNAs bind
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to the 3’ un-translated regions of mRNAs. MiRNAs regulate the expression of various
downstream target genes and through feedback regulation mechanisms, the products of miRNA
and their target genes can amplify or inhibit a signal43. Therefore, an alteration of any capacity
can regulate physiologic cellular functions. During some early studies, it was found that there
was a higher expression of miRNA-21, miRNA-27b, miRNA-103, and miRNA-155 in obesity
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and PCOS44. There are about 6 miRNAs, miRNA-93, miRNA-223, miRNA-320, miR-222, miR146a, and miR-30c that have been associated with PCOS either individually or as part of a
panel4-6.
A recent study found that there was a down regulation of the insulin sensitive-glucose
transporter GLUT4 gene expression by miRNA-93 in adipose tissue. MiR-93 is intronic,
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meaning that it doesn’t code for amino acids. Through multiple studies it was hypothesized that
miR-93 is transcribed with its host gene, MCM7. It is integrated into the 13th intron of MCM7
and since it is intronic, it could be transcribed, or it could have its own promoter45. A different
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study concluded that PCOS patients with insulin resistance showed an overexpression of
miRNA-93 in adipose tissue, but it was discordant for the expression of its host gene MCM745.
MiR-320 has been associated with PCOS and has been shown to be involved in growth,
proliferation, and the cell cycle. The miR-320 functions to regulate molecules, especially ET-1,
5

its target gene. ET-1, a molecule produced by endothelial cells, is a bioactive peptide that
promotes cell mitosis, participates in tumor growth, and induces mitosis within tumor growth.
ET-1 is the most potent biomolecule, but there are two other types of ET including ET-2 and ET34 .
Another study focused on miR-222, miR-146a, and miR-30c used in a panel. These were
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chosen due to miR-222 association with insulin sensitivity along with its marked expression in
Type 2 Diabetes46. MiR-146a was shown to suppress the release of progesterone, androgens, and
estrogens along with general secretion47. Finally, all three MiRNAs have shown involvement in
signaling pathways such as Wnt, MAPK, and Jak-STAT, apoptosis and endocrine, suggesting a
role the pathogenesis of PCOS.
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Increased Expression of miRNA-93 in Women with PCOS
Studies have compared miRNA-93 and miRNA-223 expression in women PCOS48.
MiRNA-93 was studied in comparison with miRNA-223 to determine their correlation to the
metabolic indices found in individuals with PCOS compared to the normal controls that were age
and BMI matched. In the study, 25 medication naïve women aged 18-45 years with PCOS and
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biochemical hyperandrogenemia were recruited from the local PCOS biobank. The control
consisted of 20 normal women who were also recruited from the PCOS bank aged 20-44 years of
whom were also age and BMI matched. The subjects were diagnosed with PCOS using the
Rotterdam criteria including evidence of hyperandrogenemia, specifically with a Ferriman-
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Gallwey score greater than 8 and free androgen index greater than 4. Additionally, the presence
of oligomenorrhea and polycystic ovaries on the transvaginal ultrasound were identified.
Conditions

such

as

diabetes

mellitus,

non-classical

21-hydroxylase

deficiency,

hyperprolactinemia, Cushing’s disease and androgen-secreting tumors were excluded5.
5

Both miRNA-93 and mRNA-223 were determined by total RNA reverse transcription
and qPCR. Both an unpaired t-test and a ROC curve were used to determine their discriminating
effects. The results showed that insulin, HOMA-beta, and testosterone were significantly
increased in the PCOS group and HOMA-IR did not differ when looking at all the parameters
(Table 3)5. Both the expression of miRNA-93 and miRNA-223 were increased in PCOS when

10

compared to the control group. The sensitivity, specificity, and AUC of miR-223 and miR-93
were 0.56, 0.72 and 0.60 (95% Cl: 0.5-0.82) and 0.64, 0.76 and 0.72 (95% Cl: 0.58-0.86)
respectively5. With these results, miR-93 is more efficient than miR-223 as a biomarker for
diagnosing PCOS. After the data was analyzed, it was determined that the area under the ROC
curve for miRNA-223 and miRNA-93 were 0.66 and 0.72 respectively (Figure 4)5.
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Due to the sensitivity and specificity values from the ROC curves being too low,
miRNA-93 may not be able to serve as a single diagnostic test, rather it can serve as a positive
diagnosis of PCOS rather than being one by exclusion. The authors concluded that there was a
correlation between increased circulating levels of miR-93 and miR-233 and elevated insulin and
testosterone levels. No association between elevated miRNA levels and insulin resistance or

20

hyperandrogenemia was found. It was strongly suggested that elevated miR-93 expression in the
plasma may represent a non-invasive biomarker for the diagnosis of PCOS5.
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Associating MiRNA-320 and ET-1 with the Pathogenesis of PCOS
This particular study involved 60 patients with PCOS and 40 individuals who were part
of the control. The PCOS subjects were then divided based on the HOMA-IR or homeostasis
model assessment of insulin resistance depending on the presence or absence of IR. ELISA was
5

used to measure ET-1 levels and PCR or the polymerase chain reaction was used to determine
MiRNA-320 expression levels4.
Studies showed that expression levels of miRNA-320 in PCOS patients were
significantly lower compared to the control group4. It was seen that there was a significant
negative correlation between serum miRNA-320 expression levels and ET-1 present (Figure 5,

10

Figure 6)4. Additionally, PCOS and insulin resistance patients had significantly higher serum
levels of ET-1 compared to PCOS women without insulin resistance. It was concluded that
miRNA-320 acts through its target ET-1 and inhibits IR in patients with PCOS. MiRNA-320
uses IRS-1 regulating the ERK ½ signaling pathway and miRNA-320 controls pathways
involved in follicular maturation4.

15

Increased expression of miRNA-222, miRNA-146a and miR-30c with the Pathogenesis of
PCOS
In this study, 68 patients who were diagnosed with PCOS were obtained from the
Nanjing Maternity and Child Health Hospital ages 23.8 to 29.4 years. 68 healthy controls were
also age matched and recruited from the same hospital and were between the ages of 24.5 to 31.3

20

years. Both hyperandrogenism and chronic anovulation were excluded. During phase I of the
study, biomarkers were discovered using TLDA chip assays. During phase II, the quantitative
reverse transcription-polymerase chain reaction was used on all subjects to validate the miRNAs

20

that were screened. Both the Mann-Whitney U-test and determining the area under the ROC
curve (AUC) and 95% confidence interval (CI) were used for statistical analyses6.
During phase I of the study, 8 up-regulated mRNAs were found including miR-222, miR16, miR-19a, miR-106a, miR-30c, miR-146a, miR-24 and miR-186 along with one-down
5

regulated miRNA-320. During phase II, three miRNAs were found to be significantly up
regulated in women with PCOS compared to those without. These include miR-222, miR-146a,
and miR-30c, with p-values of 0.014, 0.024, and 0.031 respectively. The results showed AUC
values of 0.799, 0.706, and 0.688 for miR-222, miR-146a, and miR-30c, respectively. It was also
seen that the largest area under the ROC curve was present during the combination of the three

10

miRNAs (Figure 7)6.
Conclusion
It must be noted that there are no biomarkers that are currently being used in a clinical
setting. The biomarkers discussed and characterized above for both endometriosis and PCOS are
currently pre-clinical studies but based on the studies present as strong suggestive tools for

15

potential diagnosis of the conditions. As stated previously, these non-invasive biomarkers would
be particularly helpful in diagnosing benign gynecological conditions early on. The complexity
of the diagnosis of endometriosis lies in the fact that invasive surgery or a laparoscopic
procedure is needed. On the other hand, the complexity of the diagnosis of PCOS lies in fact that
it is a diagnosed based on multiple criteria and particularly exclusion. Overall, it was seen that

20

MiRNAs play a big role in potentially diagnosing both conditions. It would be difficult to rank
these biomarkers from least effective to most effective since AUC values can change when the
biomarkers are used in as a single diagnostic test as opposed to when the biomarkers are part of a
panel.
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Figure 1. Revised American Society for Repro. Medicine Classification of Endometriosis10

26

Table 1. High-scoring protein of interest identified by TMT 3D-LC-MS/MS profiling2.
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Table 2. Performance of cross-validated multi-marker models for discriminating Endometriosis
from control groups2.
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Figure 2. ROC curve and AUC of the serum Gal-9 ELISA1
5
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5

Figure 3. (C) Diagnostic value of hsa-miRNA-154-5p for endometriosis expressed by ROC
curve analysis (left) of the log2 transformed expression data (right) obtained in a cohort of n=64
cases and controls. The AUC and P-values are indicated in the graph. (D) Diagnostic
performance of the combined four DE miRNA in a cohort of n=83 when analyzed together (left)
or in combination with the clinical parameters age and BMI (right) is graphically presented. The
AUC and corresponding P-values for each test are indicated in the graphs3.
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Figure 4. ROC curve analysis of (A) miR-233 and (B) miR-93 to discriminate women with
PCOS from healthy controls5.
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5

Table 3. Demographics, biochemical and clinical markers for the PCOS and control group
(unpaired t test) (BMI, body mass index; FAI, free androgen index; SHBG, sex hormone
binding globulin; HOMA-IR, homeostatic model assessment-insulin resistance; HOMA-beta,
homeostatic model assessment-insulin beta cell sensitivity; hsCRP, high sensitivity C-reactive
protein.)5.
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5

Figure 5. ROC curve for serum miRNA-320 expression level or prediction of PCOS4.

Figure 6. ROC curve for serum ET-1 expression level or prediction of PCOS4.
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5

Figure 7. ROC curve analysis using three miRNAs to discriminate women with PCOS from
healthy controls. (A) miR-222, (B) miR-146a, (C) miR-30c, (D) ROC curve of the combination
of the 3 miRNAs using multiple logistic regression analysis. The combination of the three
miRNAs (miR-222, miR146-a and miR-30c) yielded the largest area under the ROC curve
(AUC)6.
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